|Lab of:||Nima Sharifi, MD|
A postdoctoral position supported by the Howard Hughes Medical Institute and the National Cancer Institute is available in the laboratory of Dr. Nima Sharifi at the Cleveland Clinic.
Our laboratory is focused on molecular mechanisms of androgen synthesis and androgen receptor (AR) gain-of-function that lead to resistance to androgen deprivation therapy and the translational relevance thereof. Areas of interest in this laboratory include:
We recently discovered the first example of a gain-of-function in a steroid-synthesizing enzyme that enables prostate cancer resistance to hormonal therapy (Chang, et al. Cell. 2013 154(5):1074-1084). We are pursuing similar mechanisms and developing new treatment modalities based on these discoveries. Our work was featured in an "Editor's Choice" in Science Translational Medicine and a "Research Watch" in Cancer Discovery.
We have also discovered that prostate cancer becomes resistant to hormonal therapy by the synthesis of dihydrotestosterone through a pathway that circumvents testosterone, instead requiring α-androstanedione, a previously underappreciated intermediate metabolite. This metabolic pathway occurs commonly in all models and patient tumors tested (Chang, et al. Proc Natl Acad Sci USA. 2011 Aug 16;108(33):13728-33). Our unprecedented approach to the identification of metabolic pathways in tumors from patients redefines the fundamental mechanism that drives the progression of resistant tumors. This work was featured as a Research Highlight in Nature Reviews Urology (Nat Rev Urol. 2011 Sep 8;8(9):470) and given a "must read" review by the Faculty of 1000.
The position will provide a unique and multidisciplinary exposure to tumor metabolism, molecular oncology, drug development and clinical trials. This research program is supported by the Howard Hughes Medical Institute, the American Cancer Society, the Prostate Cancer Foundation, the Department of Defense Prostate Cancer Research Program and the National Institutes of Health. Further details are available at the following link: https://www.lerner.ccf.org/cancerbio/sharifi/#lab
The candidate should hold a doctoral degree with a background in molecular biology, metabolism or cancer biology.
Candidates with an interest in the position should send their cv and contact information for 3 references to:
Nima Sharifi, MD
Kendrick Family Chair for Prostate Cancer Research
Department of Cancer Biology
Lerner Research Institute
Cleveland Clinic, 9500 Euclid Avenue
Cleveland, OH 44195
|Current as of:||March 25, 2014|
|Lab of:||Susann M. Brady-Kalnay, PhD|
|Department:||Molecular Biology and Microbiology|
A postdoctoral position is available to develop molecular imaging agents and MRI imaging protocols aimed at detecting small clusters of tumor cells. We are recruiting a highly motivated and creative team player to help us develop innovative methods in molecular imaging of cancer. This NIH funded work is being conducted at Case Western Reserve University and University Hospitals Case Medical Center in Cleveland, OH. The Principal investigator is Susann Brady-Kalnay, PhD, Professor of Molecular Biology and Microbiology at Case Western Reserve University. The research team also includes Mark Griswold, PhD, Professor of Radiology; Vikas Gulani, Assistant Professor of Radiology; Zheng-Rong Lu, PhD, Professor of Biomedical Engineering; and David Wilson, Professor, Biomedical Engineering.
The project will involve members of the Case Center for Imaging Research. The scientific team includes postdocs, graduate students, and research associates with expertise in physics, chemistry, tumor biology and biomedical engineering. Minimum qualifications include a Ph.D. in chemistry, physics, biology, or biomedical engineering. Experience working with magnetic resonance imaging and a record of scientific productivity are required. Experience with Bruker Paravision systems is advantageous. The position is open for a 2-3 year postdoctoral fellowship. U.S. citizens and permanent residents will be considered for a training grant position.
Interested individuals should send their CV Susann Brady-Kalnay (email@example.com), who will provide further information on formal application procedures.
Susann M. Brady-Kalnay, PhD
Department of Molecular Biology and Microbiology
Case Western Reserve University
Cleveland, OH 44106
|Current as of:||November 13, 2013|
|Lab of:||Mark W. Jackson, PhD|
|Research Themes:||Common defining characteristics of human cancer cells are their insensitivity to anti-proliferative signals and their acquisition of immortality. Research in my lab utilizes in vitro models of human mammary epithelial cell (HMEC) transformation, whereby known genetic events involved in HMEC transformation are replaced by "random" genetic events. This approach has provided us with new and exciting candidates involved in breast cancer development. An appropriate candidate will be highly motivated, have a track record of research accomplishments, including peer-reviewed publications and meeting presentations, and have a strong background in cancer cell biology or signal transduction.|
|Required Skills:||Candidate will be proficient in techniques such as: tissue culture; xenograft transplation of human cancer cells into mice (surgical experience preferred); virus production and infection of cells; analysis of protein, RNA and DNA using a variety of techniques (Western, Northern, Southern blotting, PCR, immunofluorescent microscopy, flow cytometry). Excellent communication and organization skills required.|
Interested individuals should send their CV and the names of three references to:
Mark W. Jackson, PhD
Department of Pathology
Case Western Reserve University School of Medicine
Case Comprehensive Cancer Center
2103 Cornell Road, WRB 3-134
Cleveland, OH 44106
|Current as of:||July 25, 2013|
|Lab of:||Monica M. Montano, PhD|
|Research Themes:||Estrogen action in hormone-responsive malignancies|
Monica M. Montano, PhD
Associate Professor, Pharmacology
Case School of Medicine
10900 Euclid Avenue
H.G. Wood Building, Room W307
Cleveland, Ohio 44106
Phone: 216.368.3378 or 216.368.5317
|Current as of:||September 17, 2013|